Project Grant R01CA303840
Award Date 7/20/26
Completion Date 6/30/31
Dollars Obligated $744K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
- The National Cancer Institute awarded Sanford Burnham Prebys Medical Discovery Institute $646,134 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate transcriptional mechanisms of anti-tumor immunity and identify strategies to enhance immune checkpoint blockade efficacy. The funded research mechanistically dissects how degradation of the transcription factor Helios (IKZF2) boosts anti-tumor T cell responses and determines whether Helios degradation...
- The National Cancer Institute awarded Scripps Research Institute $748,410 on June 19, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop heterobifunctional degraders targeting the glycoimmune checkpoints SIGLEC-7 and SIGLEC-9 for cancer immunotherapy. The project, which runs through May 31, 2031, will construct an unnatural sialic acid derivative library and use cell-based assays to identify optimized ligands with high affinity and exclusive specificity for both...
- The National Cancer Institute awarded the University of Kansas Medical Center Research Institute, Inc. $398,544 on April 8, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct pre-clinical evaluation of a highly selective SMARCA2 degrader in therapy-resistant triple-negative breast cancer. The research addresses mechanisms of resistance to neoadjuvant systemic therapy in triple-negative breast cancer patients with residual disease. The project leverages the recipient's...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $577,331 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to repurpose HSP90 inhibitors as a condensate-directed therapy for receptor tyrosine kinase fusion-driven cancers. The project targets cancers driven by RTK fusions such as EML4-ALK and CCDC6-RET, which account for 3–5 percent of all cancer diagnoses and approximately 225,000 new lung cancer patients annually worldwide. The...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $640,466 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop covalent protein radiopharmaceuticals for targeted radionuclide therapy in cancer treatment. The project, funded through a Project Grant (R01CA309883), addresses a fundamental challenge in radiopharmaceutical design: balancing tumor uptake efficacy with safety by minimizing radiation exposure to normal...
- The National Institutes of Health National Cancer Institute awarded the University of California, San Diego $771,811 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to identify small molecule activators of type I interferon signaling for cancer treatment. The research focuses on discovering and developing small molecule inhibitors targeting USP18, a ubiquitin protease that suppresses the type I interferon response through negative feedback regulation. Prior work...
- The National Cancer Institute awarded Yale University $482,312 as a Project Grant on April 2, 2026, to develop a novel approach for inactivating regulatory T (Treg) cells through targeted protein degradation as a strategy to enhance cancer immunotherapy response and reduce immune-related adverse events. The funded research addresses immunotherapy resistance in cancers unresponsive to existing checkpoint blockade, cytokine therapy, and chimeric antigen receptor-based cell therapy. Preliminary...
- The National Cancer Institute awarded The Institute For Cancer Research $766,439 on April 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct research on intratumor heterogeneity as a correlate of clinical outcome in patients avoiding radical cystectomy. The research addresses the clinical need for better patient selection and surveillance tools for bladder cancer patients seeking to avoid radical cystectomy following neoadjuvant chemotherapy. Two completed...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $153,330 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop a radiotheranostic platform targeting androgen receptor in prostate cancer. The funded work develops non-steroidal androgen receptor agonists for DNA-targeted Auger electron therapy to address treatment-resistant prostate cancer. The project combines disease monitoring and targeted cytotoxic agent delivery using...
- The National Cancer Institute awarded the University of California, San Diego $663,196 on July 20, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop high-throughput screening assays and discover chemical probes targeting UBR2, a ubiquitin E3 ligase, for treatment of cancer-related and diabetes-induced cachexia. The project runs through June 30, 2029, with work performed in La Jolla, California. Aim 1 will develop 1536-well high-throughput screening-compatible assays...